Who
Adam Morgan
Director
Company insider
Files Form 4 as: Director and Other, Heron Therapeutics; Director and 10% owner, Alimera Sciences.
In numbers
- Trades disclosed
- 25
- Buys
- 3
- Sells
- 0
- Bought
- $8.4M
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 22 Feb 2023
- Last trade
- 30 Jan 2026
- Last filed
- 3 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jan 2026filed 3 Feb 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code A | —53,960 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code A | —53,960 at $0.00 | filing |
| 8 Aug 2025filed 12 Aug 2025 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $1.1M70,012 at $15.00 | filing |
| 8 Aug 2025filed 12 Aug 2025 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Bought | $2.6M1,766,546 at $1.50 | filing |
| 31 Jan 2025filed 4 Feb 2025 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,900 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code A | —17,950 at $0.00 | filing |
| 30 Jan 2025filed 3 Feb 2025 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $62K35,900 at $1.73 | filing |
| 30 Jan 2025filed 3 Feb 2025 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code A | —17,950 at $0.00 | filing |
| 19 Jan 2024filed 19 Jan 2024 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —83,685 at $0.00 | filing |
| 19 Jan 2024filed 19 Jan 2024 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code A | —13,948 at $0.00 | filing |
| 15 Aug 2023filed 17 Aug 2023 | Alimera Sciencesoption or derivative | SEC FORM 4 Code C | —8,117 | filing |
| 15 Aug 2023filed 17 Aug 2023 | Alimera Sciencesoption or derivative | SEC FORM 4 Code C | —7,000 | filing |
| 15 Aug 2023filed 17 Aug 2023 | Alimera Sciencesoption or derivative | SEC FORM 4 Code C | —6,000 | filing |
| 15 Aug 2023filed 17 Aug 2023 | Alimera Sciences | SEC FORM 4 Code C | $8.2M4,845,392 at $1.70 | filing |
| 15 Aug 2023filed 17 Aug 2023 | Alimera Sciences | SEC FORM 4 Code C | $6.1M2,924,762 at $2.10 | filing |
| 15 Aug 2023filed 17 Aug 2023 | Alimera Sciences | SEC FORM 4 Code C | $7.1M4,178,725 at $1.70 | filing |
| 21 Jul 2023filed 25 Jul 2023 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $1.6M1,162,891 at $1.37 | filing |
| 21 Jul 2023filed 25 Jul 2023 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Bought | $3.4M2,486,744 at $1.37 | filing |
| 17 May 2023filed 19 May 2023 | Alimera Sciencesoption or derivative | SEC FORM 4 Code P | —8,117 | filing |
| 17 May 2023filed 19 May 2023 | Alimera Sciencesoption or derivative | SEC FORM 4 Code J | —2,057,143 | filing |
News
No headline names them, or the companies they trade most, lately.